Last10K.com

Nuo Therapeutics, Inc. (AURX) SEC Filing 10-Q Quarterly report for the period ending Saturday, June 30, 2018

Nuo Therapeutics, Inc.

HISTORY TOOLS
CIK: 1091596 Ticker: AURX
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2018
Aug. 13, 2018
Document Information [Line Items]  
Entity Registrant NameNuo Therapeutics, Inc. 
Entity Central Index Key0001091596 
Trading Symbolaurx 
Current Fiscal Year End Date--12-31 
Entity Filer CategorySmaller Reporting Company 
Entity Current Reporting StatusYes 
Entity Voluntary FilersNo 
Entity Well-known Seasoned IssuerNo 
Entity Common Stock, Shares Outstanding (in shares) 23,722,400
Document Type10-Q 
Document Period End DateJun. 30, 2018 
Document Fiscal Year Focus2018 
Document Fiscal Period FocusQ2 
Amendment Flagfalse 

View differences made from one quarter to another to evaluate Nuo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Nuo Therapeutics, Inc..

Continue

Assess how Nuo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Nuo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (Current Period Unaudited)
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Note 1 - Description Of Business And Bankruptcy Proceedings
Note 1 - Description Of Business And Bankruptcy Proceedings (Details Textual)
Note 2 - Liquidity And Summary Of Significant Accounting Policies - Anti-Dilutive Securities Excluded From The Computation Of Diluted Earnings (Loss) Per Share (Details)
Note 2 - Liquidity And Summary Of Significant Accounting Principles
Note 2 - Liquidity And Summary Of Significant Accounting Principles (Details Textual)
Note 2 - Liquidity And Summary Of Significant Accounting Principles (Tables)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Adoption Of Asu 2016-18 (Details)
Note 2 - Liquidity And Summary Of Significant Accounting Principles - Summary Of Concentration Risk (Details)
Note 3 - Distribution, Licensing And Collaboration Arrangements
Note 3 - Distribution, Licensing And Collaboration Arrangements (Details Textual)
Note 4 - Receivables
Note 4 - Receivables (Details Textual)
Note 4 - Receivables (Tables)
Note 4 - Receivables - Accounts And Other Receivable, Net (Details)
Note 5 - Property And Equipment
Note 5 - Property And Equipment (Details Textual)
Note 5 - Property And Equipment (Tables)
Note 5 - Property And Equipment - Property And Equipment, Net (Details)
Note 6 - Equity And Stock-Based Compensation
Note 6 - Equity And Stock-Based Compensation (Details Textual)
Note 6 - Equity And Stock-Based Compensation (Tables)
Note 6 - Equity And Stock-Based Compensation - Stock Option Activity (Details)
Note 6 - Equity And Stock-Based Compensation - Stock-Based Compensation Expense (Details)
Note 7 - Commitments And Contingencies
Note 7 - Commitments And Contingencies (Details Textual)
Note 8 - Subsequent Events
Note 8 - Subsequent Events (Details Textual)
Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Nuo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: AURX
CIK: 1091596
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-18-015352
Submitted to the SEC: Mon Aug 13 2018 4:31:25 PM EST
Accepted by the SEC: Mon Aug 13 2018
Period: Saturday, June 30, 2018
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aurx/0001437749-18-015352.htm